AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial

被引：4
|
作者：
Strickler, J. H. [1 ]
Fakih, M. [2 ]
Price, T. J. [3 ]
Desai, J. [4 ]
Durm, G. [5 ]
Krauss, J. C. [6 ]
Kuboki, Y. [7 ]
Kim, T. W. [8 ]
Sacher, A. [9 ]
Henary, H. [10 ]
Kim, J. [11 ]
Hong, D. S. [12 ]
机构：
[1] Duke Canc Ctr, Med, Durham, NC USA
[2] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
[3] Queen Elizabeth Hosp, Emergency Dept, Med Oncol, Woodville, SA, Australia
[4] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[5] Dept Med, Div Hematol Oncol, Indianapolis, IN USA
[6] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[7] Canc Inst Hosp JFCR, Dept Expt Therapeut & GI Oncol, Tokyo, Japan
[8] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] Princess Margaret Canc Ctr, Med Oncol & Hematol Dept, Toronto, ON, Canada
[10] Amgen Inc, Early Dev Oncol Dept, Thousand Oaks, CA USA
[11] Amgen Inc, Biostat, Thousand Oaks, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeuitcs Dept, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
83MO
引用
收藏
页码：S1274 / S1275
页数：2
相关论文
共 34 条
  • [1] AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial
    Strickler, J.
    Fakih, M.
    Price, T.
    Desai, J.
    Durm, G.
    Krauss, J.
    Kuboki, Y.
    Kim, T.
    Sacher, A.
    Henary, H.
    Kim, J.
    Hong, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S226 - S226
  • [2] CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
    Fakih, Marwan
    Desai, Jayesh
    Kuboki, Yasutoshi
    Strickler, John H.
    Price, Timothy Jay
    Durm, Greg Andrew
    Falchook, Gerald Steven
    Denlinger, Crystal S.
    Krauss, John C.
    Shapiro, Geoffrey
    Kim, Tae Won
    Park, Keunchil
    Coveler, Andrew L.
    Munster, Pamela N.
    Li, Bob T.
    Kim, June
    Henary, Haby Adel
    Ngarmchamnanrith, Gataree
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
    Govindan, R.
    Fakih, M. G.
    Price, T. J.
    Falchook, G. S.
    Desai, J.
    Kuo, J. C.
    Strickler, J. H.
    Krauss, J. C.
    Li, B. T.
    Denlinger, C. S.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 163 - +
  • [4] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [5] CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
    Hong, David S.
    Kuo, James
    Sacher, Adrian G.
    Barlesi, Fabrice
    Besse, Benjamin
    Kuboki, Yasutoshi
    Dy, Grace K.
    Dembla, Vikas
    Krauss, John C.
    Burns, Timothy F.
    Kim, June
    Henary, Haby
    Ngarmchamnanrith, Gataree
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study
    Kuboki, Yasutoshi
    Murciano-Goroff, Yonina R.
    Yaeger, Rona
    Cassier, Philippe Alexandre
    Heist, Rebecca Suk
    Fujiwara, Yutaka
    Deming, Dustin A.
    Ammakkanavar, Natraj
    Patnaik, Amita
    Shimizu, Toshio
    Call, Justin
    Han, Sae-Won
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Balar, Arjun Vasant
    Koyama, Takafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 94 - 94
  • [7] Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor
    Christensen, James G.
    Fell, Jay B.
    Marx, Matthew A.
    Fischer, John
    Hallin, Jill
    Calinisan, Andrew
    Baer, Brian
    Burkhard, Michael
    Blake, James
    Vigers, Guy
    Aranda, Ruth
    Hargis, Lauren
    Briere, David
    Engstrom, Lars
    Olson, Peter
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
    Fakih, Marwan
    Durm, Greg Andrew
    Govindan, Ramaswamy
    Falchook, Gerald Steven
    Soman, Neelesh
    Henary, Haby Adel
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
    Zhou, Q.
    Meng, X.
    Sun, L.
    Huang, D.
    Yang, N.
    Yu, Y.
    Zhao, M.
    Zhuang, W.
    Hu, Y.
    Pan, Y.
    Sun, M.
    Shan, J.
    Guo, R.
    Chu, Q.
    Xu, C.
    Lin, J.
    Huang, J.
    Huang, M.
    Zhang, S.
    Wu, Y. L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S42 - S42
  • [10] A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress).
    Ammakkanavar, Natraj Reddy
    Call, Justin
    Shimizu, Toshio
    Kuboki, Yasutoshi
    Liu, Shiyao
    Willard, Melinda D.
    Axelson, Michael
    Heist, Rebecca S.
    Patnaik, Amita
    CANCER RESEARCH, 2022, 82 (12)
1234